S2157 is a potent lysine-specific demethylase 1 (LSD1) inhibitor that increases H3K9 methylation and corresponding H3K27 deacetylation at super-enhancer regions; it suppresses transcription of NOTCH3 and TAL1 genes, thereby inducing apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells; it effectively crosses the blood-brain barrier and nearly eradicates central nervous system leukemia in T-ALL xenograft mouse models.